Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080081 | 0.91 | MAPT (0.42) | ADORA3ADORA2AADORA1PTGER1MAPT | |
| SCHEMBL6080462 | 0.90 | BACE1 (0.47) | MAPT | |
| SCHEMBL6080132 | 0.80 | HRH4 (0.46) | HRH4AVPR2AVPR1AMAPK1HTR6 | |
| SCHEMBL6080351 | 0.80 | MAPT (0.49) | ADORA3ADORA2AADORA1PTGER1MAPT | |
| SCHEMBL6079779 | 0.80 | KDM4A (0.42) | HRH4 | |
| SCHEMBL6594367 | 0.79 | HRH4 (0.47) | HRH4AVPR2AVPR1AADORA3ADORA2A | |
| SCHEMBL6080005 | 0.79 | MAPT (0.48) | ADORA3ADORA2AADORA1PTGER1MAPT | |
| SCHEMBL6080162 | 0.74 | ALDH1A1 (0.46) | HRH4ADORA3ADORA2AADORA1MAPT | |
| SCHEMBL6080232 | 0.74 | PTGER1 (0.43) | ADORA3ADORA2AADORA1PTGER1MAPT | |
| SCHEMBL6080599 | 0.74 | ADORA1 (0.46) | ADORA3ADORA2AADORA1PTGER1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | HRH4 619/4885AVPR2 1922/4885AVPR1A 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.